These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11266165)

  • 1. Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
    Renau TE; Léger R; Flamme EM; She MW; Gannon CL; Mathias KM; Lomovskaya O; Chamberland S; Lee VJ; Ohta T; Nakayama K; Ishida Y
    Bioorg Med Chem Lett; 2001 Mar; 11(5):663-7. PubMed ID: 11266165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
    Renau TE; Léger R; Flamme EM; Sangalang J; She MW; Yen R; Gannon CL; Griffith D; Chamberland S; Lomovskaya O; Hecker SJ; Lee VJ; Ohta T; Nakayama K
    J Med Chem; 1999 Dec; 42(24):4928-31. PubMed ID: 10585202
    [No Abstract]   [Full Text] [Related]  

  • 3. Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
    Renau TE; Léger R; Yen R; She MW; Flamme EM; Sangalang J; Gannon CL; Chamberland S; Lomovskaya O; Lee VJ
    Bioorg Med Chem Lett; 2002 Mar; 12(5):763-6. PubMed ID: 11858997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
    Renau TE; Léger R; Filonova L; Flamme EM; Wang M; Yen R; Madsen D; Griffith D; Chamberland S; Dudley MN; Lee VJ; Lomovskaya O; Watkins WJ; Ohta T; Nakayama K; Ishida Y
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2755-8. PubMed ID: 12873508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.
    Lomovskaya O; Warren MS; Lee A; Galazzo J; Fronko R; Lee M; Blais J; Cho D; Chamberland S; Renau T; Leger R; Hecker S; Watkins W; Hoshino K; Ishida H; Lee VJ
    Antimicrob Agents Chemother; 2001 Jan; 45(1):105-16. PubMed ID: 11120952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors.
    Watkins WJ; Landaverry Y; Léger R; Litman R; Renau TE; Williams N; Yen R; Zhang JZ; Chamberland S; Madsen D; Griffith D; Tembe V; Huie K; Dudley MN
    Bioorg Med Chem Lett; 2003 Dec; 13(23):4241-4. PubMed ID: 14623009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.
    Nakayama K; Ishida Y; Ohtsuka M; Kawato H; Yoshida K; Yokomizo Y; Ohta T; Hoshino K; Otani T; Kurosaka Y; Yoshida K; Ishida H; Lee VJ; Renau TE; Watkins WJ
    Bioorg Med Chem Lett; 2003 Dec; 13(23):4205-8. PubMed ID: 14623002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa.
    Kriengkauykiat J; Porter E; Lomovskaya O; Wong-Beringer A
    Antimicrob Agents Chemother; 2005 Feb; 49(2):565-70. PubMed ID: 15673734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
    Lister PD; Wolter DJ
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin penetrates human monocytes and enhances intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa.
    Smith RP; Baltch AL; Franke MA; Michelsen PB; Bopp LH
    J Antimicrob Chemother; 2000 Apr; 45(4):483-8. PubMed ID: 10747825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?
    Bonfiglio G
    Chemotherapy; 2001; 47(4):239-42. PubMed ID: 11399859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MC-207110 Daiichi Seiyaku/Microcide Pharmaceuticals.
    Barrett JF
    Curr Opin Investig Drugs; 2001 Feb; 2(2):212-5. PubMed ID: 11816833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates.
    Coban AY; Ekinci B; Durupinar B
    Chemotherapy; 2004 Apr; 50(1):22-6. PubMed ID: 15084801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
    MacGowan AP; Wootton M; Holt HA
    J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic potential of ceftazidime plus amikacin or levofloxacin against Pseudomonas aeruginosa as determined using a checkerboard and a disk diffusion technique.
    Montanari MP; Piccoli L; Mingoia M; Marchetti F; Varaldo PE
    Diagn Microbiol Infect Dis; 2005 Oct; 53(2):157-60. PubMed ID: 16168614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents.
    Yoshida K; Nakayama K; Yokomizo Y; Ohtsuka M; Takemura M; Hoshino K; Kanda H; Namba K; Nitanai H; Zhang JZ; Lee VJ; Watkins WJ
    Bioorg Med Chem; 2006 Dec; 14(24):8506-18. PubMed ID: 16979895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
    Flynn CM; Johnson DM; Jones RN
    J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide.
    Sonnet P; Izard D; Mullié C
    Int J Antimicrob Agents; 2012 Jan; 39(1):77-80. PubMed ID: 21974858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological testing of non-fluorinated analogues of levofloxacin.
    Gray JL; Almstead JI; Gallagher CP; Hu XE; Kim NK; Taylor CJ; Twinem TL; Wallace CD; Ledoussal B
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2373-5. PubMed ID: 12824037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.